Developing Non-Antibiotic Options to Manage Mycoplasma Bovis

Background

Mycoplasma bovis is involved in bovine respiratory disease, and mycoplasma treatments are estimated to cost the beef industry $30 to $50 per head. M. bovis also causes significant welfare (lameness) problems. There is no vaccine for M. bovis. One challenge for vaccine development is that Mycoplasma can alternate which antigens proteins it expresses on the cell membrane surface. This means that some M. bovis antigens might stimulate an initial immune response, but the bacteria may be expressing different surface antigens by the time the animal’s antibodies are circulating. As a result, the immune response is always playing catch-up and doesn’t effectively combat M. bovis infections.  

These researchers want to explore molecules that may be able to interfere with the M. bovis cell membrane, so that it releases more of its cell membrane proteins. This would allow the animal’s immune system to recognize more of the M. bovis surface antigens and help it to mount a more effective immune response.  

These researchers are targeting an M. bovis enzyme that is involved in cell membrane growth. They will use results recently obtained from other bacteria that also add lipids (fats) to proteins to anchor them within the cell membrane (these are called lipoproteins). 

Objectives

• Develop an assay to screen for compounds that elicit the release of lipoproteins from M. bovis cells 
• Screen and validate safe, commercially available compounds for their ability to induce the release of M. bovis lipoproteins 

What they will do

They will develop and validate an assay to screen for drugs that can disrupt the M. bovis enzymes involved in cell membrane maturation. This will be done by replacing an E. coli gene with the M. bovis enzyme gene, along with a second gene to report when the first gene is functioning. The reporter gene will indicate the status of lipoproteins in the cell membrane. The researchers are using this approach because M. bovis is a very difficult organism to grow and work with, while E. coli is well understood, easy to grow, and easy to work with. 

The second step is to screen 2,368 FDA-approved and commercially available compounds and validate whether they can disrupt the M. bovis cell membrane. They will be tested at three different concentrations in bovine nasal and kidney tissue culture for a preliminary evaluation of animal safety. If necessary, 200 other natural extracts derived from livestock microbiomes are available for screening and testing. Compounds that work will be tested in M. bovis under different environmental conditions, using well-characterized M. bovis isolates isolated from the lung and joint of feedlot cattle. 

Implications

M. bovis has been a big problem for a long time, and we still don’t have effective solutions. This project is very early stage drug discovery research. It will not solve the mycoplasma problem, but it will explore a potential new approach that may lead to an effective solution in the future.